WHO INN approves ‘Usnoflast’ as recommended name for ZYIL1 from Zydus
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus. Studies have demonstrated that ZYIL1 is…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
ZYIL1
Zydus begins Phase II trial of ZYIL1, NLRP3 inhibitor in patients with ALS
USFDA has granted Zydus an ‘Orphan Drug Designation’ for ZYIL1 to treat patients with Cryopyrin Associated Periodic Syndrome…
Zydus to begin phase-II (a) clinical trial of oral inflammasome inhibitor in patients with…
Cryopyrin-Associated Periodic Syndrome (CAPS) is a rare life-long auto-inflammatory condition, caused by NLRP3 activating…
Zydus announces Phase I trials of ZYIL1, oral small molecule NLRP3 inflammasome inhibitor
NLRP3 inflammasomes lead to the onset and development of diseases like ARDS, auto-immune diseases, inflammatory diseases, CVDs,…
Zydus Cadila files IND application for ZYIL1, NLRP3 inflammasome inhibitor
It can selectively modulate the inflammatory responses caused by the ‘Cytokine Storm’ in ARDS, COVID19 and other inflammatory…